Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$46.55 USD
-0.83 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $46.57 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Agios Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 27 | 14 | 0 | 203 | 118 |
Cost Of Goods | 3 | 2 | 0 | 3 | 1 |
Gross Profit | 24 | 13 | 0 | 200 | 117 |
Selling & Adminstrative & Depr. & Amort Expenses | 415 | 402 | 378 | 517 | 543 |
Income After Depreciation & Amortization | -391 | -389 | -378 | -316 | -426 |
Non-Operating Income | 39 | 157 | 22 | -11 | 15 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -352 | -232 | -357 | -327 | -411 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -352 | -232 | -357 | -327 | -411 |
Extras & Discontinued Operations | 0 | 0 | 1,961 | 0 | 0 |
Net Income (GAAP) | -352 | -232 | 1,605 | -327 | -411 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -390 | -382 | -362 | -303 | -421 |
Depreciation & Amortization (Cash Flow) | 2 | 7 | 16 | 13 | 5 |
Income After Depreciation & Amortization | -391 | -389 | -378 | -316 | -426 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 55.65 | 54.79 | 60.45 | 69.00 | 60.00 |
Diluted EPS Before Non-Recurring Items | -6.33 | -4.23 | -5.90 | -4.74 | -6.86 |
Diluted Net EPS (GAAP) | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 |
Fiscal Year end for Agios Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 8.62 | 8.19 | 7.10 | 7.40 | 6.71 |
Cost Of Goods | 1.50 | 0.63 | 0.59 | 0.63 | 1.11 |
Gross Profit | 7.12 | 7.56 | 6.52 | 6.77 | 5.60 |
SG&A, R&D, and Dept/Amort Expenses | 112.94 | 99.63 | 112.80 | 107.66 | 99.31 |
Income After SG&A, R&D, and Dept/Amort Expenses | -105.82 | -92.07 | -106.28 | -100.89 | -93.71 |
Non-Operating Income | 9.70 | 10.52 | 10.34 | 9.57 | 9.89 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -96.12 | -81.55 | -95.94 | -91.32 | -83.81 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -96.12 | -81.55 | -95.94 | -91.32 | -83.81 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -96.12 | -81.55 | -95.94 | -91.32 | -83.81 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 56.80 | 56.38 | 55.90 | 55.80 | 55.60 |
Diluted EPS Before Non-Recurring Items | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 |
Diluted Net EPS (GAAP) | -1.69 | -1.45 | -1.71 | -1.64 | -1.51 |